Curaleaf Announces 1-for-3 Reverse Split for NASDAQ Uplisting

Reverse Split Mechanics and Exchange Compliance

The reverse split consolidates every three outstanding shares into one, tripling the nominal per-share price without changing total market capitalization. Curaleaf's board approved the action under authority granted at the company's 2025 annual meeting. The split applies to all common shares, warrants, and equity compensation instruments.

NASDAQ Rule 5505(a)(1) and NYSE Rule 802.01C both require a minimum bid price of $4 per share over a trailing 30-day average for continued listing. Curaleaf's Canadian Securities Exchange listing carried no such floor. For CSE-traded MSOs, the reverse split is a standard pre-uplisting step.

Rescheduling Timeline and Uplisting Trigger

The DEA's final rule moving cannabis from Schedule I to Schedule III is expected to publish in the Federal Register by June 15, 2026, according to agency filings reviewed by CannIntel. Once effective—typically 60 days post-publication—cannabis companies become eligible for major U.S. exchange listings under existing securities law.

Curaleaf hasn't filed a formal uplisting application with NASDAQ or NYSE. The reverse split positions the company to meet price and liquidity thresholds the moment rescheduling takes effect. For full background on this story, see the CannIntel topic hub on Curaleaf's NASDAQ uplisting.

280E Relief and Institutional Access

Rescheduling to Schedule III eliminates IRC §280E disallowances for cannabis businesses, unlocking ordinary business expense deductions and materially improving GAAP profitability. Curaleaf reported $1.52 billion in revenue for fiscal 2025 but paid an effective federal tax rate exceeding 70% due to 280E.

U.S. exchange listing opens institutional capital channels currently restricted by compliance mandates. Mutual funds, pension plans, and index trackers can't hold CSE or OTC securities under most investment policy statements. NASDAQ or NYSE listing removes that barrier.

• Estimated 280E tax savings for Curaleaf: $180-220 million annually at current revenue run rate
• Institutional ownership in U.S.-listed cannabis peers averages 22%; CSE-listed MSOs average 4%
• NASDAQ minimum market cap requirement: $50 million (Curaleaf exceeds $2 billion)

Shareholder Impact and Trading Mechanics

Existing shareholders will see their share count reduced by two-thirds and per-share price multiplied by three, with no change in total position value. Fractional shares resulting from the split will be rounded to the nearest whole share or paid in cash, depending on the holder's brokerage.

The company's ticker symbol on the CSE remains CURA. Post-split, outstanding shares drop from approximately 680 million to 227 million. Options and warrants adjust proportionally under anti-dilution clauses in the equity plan.

Competitive Positioning Among MSOs

Curaleaf joins Trulieve, Green Thumb Industries, and Cresco Labs in executing reverse splits ahead of anticipated U.S. exchange access. Trulieve completed a 1-for-10 reverse split in March 2026. Green Thumb announced a 1-for-5 split scheduled for June.

Staggered timing reflects differences in current share price and capital structure. Curaleaf's more modest 1-for-3 ratio suggests management confidence in near-term price appreciation post-280E relief. The company operates 156 dispensaries across 18 states—the largest U.S. retail footprint by store count.

Three indicators matter now. First, the DEA final rule effective date. Second, Curaleaf's formal exchange application filing. Third, whether institutional buying accelerates in the 60-day window between rescheduling and uplisting approval.